Datapoint: FDA Approves High-Concentration Humira Biosimilar

The FDA last week approved Samsung Bioepis Co., Ltd. and Organon & Co.’s high-concentration, citrate-free Humira biosimilar, Hadlima, across seven of Humira’s indications. The injectable was previously approved in its low-concentration formulation. Hadlima, like all other approved Humira biosimilars, cannot launch earlier than July 1, 2023. Under the pharmacy benefit, Humira holds covered or better status for 98% of all insured lives. About 13% of lives have preferred access to Humira, growing to 64% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 8/22/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 29

Datapoint: Nebraska Awards Medicaid Contracts

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 28

Datapoint: Lilly Scores Sweeping Label Expansion for Retevmo

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 27

Datapoint: Judge Says United Can Complete Change Healthcare Deal

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today